Evaluation of three rhenium-188 candidates for intravascular radiation therapy with liquid-filled balloons to prevent restenosis

被引:19
作者
Lin, WY
Tsai, SC
Hsieh, BT
Lee, TW
Ting, G
Wang, SJ
机构
[1] Inst Nucl Energy Res, Lung Tan, Taiwan
[2] Show Chwan Mem Hosp, Dept Nucl Med, Changhua, Taiwan
[3] Taichung Vet Gen Hosp, Dept Nucl Med, Taichung 407, Taiwan
关键词
rhenium-188; MAG3; rhenium-188 pentetic acid; perrhenate; intravascular brachytherapy; restenosis;
D O I
10.1067/mnc.2000.102919
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background, Intravascular brachytherapy is an effective method for inhibiting coronary restenosis after percutaneous transluminal coronary angioplasty, A new concept for preventing restenosis is the use of a liquid-filled balloon containing a beta-ray-emitting radioisotope, Generator-produced rhenium-188 (Re-188) is a good candidate for intravascular brachytherapy. However, in the unlikely event of balloon rupture, release of Re-188 perrhenate may cause a high radiation dose to the thyroid and stomach. In this study, we compared the biodistributions of three Re-188 preparations (Re-188 perrhenate, Re-188 pentetic acid [DTPA], and Re-188 MAG3) to assess the radiation dose to organs in a rat model that mimicked balloon rupture. Methods and Results. After injection of Re-188 preparations intravenously, rats were killed at 10 minutes, 30 minutes, 60 minutes, 2 hours, and 6 hours (n = 5/group), Tissue concentrations were calculated and expressed as percent injected dose per gram or per milliliter. In addition, urine excretion and thyroid gland uptake were evaluated in rats (n = 5/group) with a gamma camera after administration of 37 MBq (1 mCi) of each agent, Our data showed all 3 agents were excreted primarily via urine. In the Re-188 MAG3 group, 82% was excreted within 1 hour, but in the Re-188 perrhenate group, only 28% was excreted. The biodistribution data for these agents revealed that radioactivity levels in the stomach and the thyroid gland were high in the perrhenate group but low in the Re-188 DTPA and Re-188 MAG3 groups. The concentration levels in other tissues including lung, liver, testis, muscle, and blood were low throughout this study for all 3 agents. The thyroid radiation values were 0.163, 0.0167, and 0.00728 mGy/MBq for Re-188 perrhenate, Re-188 DTPA, and Re-188 MAG3, respectively. The stomach radiation values were 0.127 mGy/MBq for Re-188 perrhenate, 0.013 mGy/MBq for Re-188 DTPA, and 0.0104 mGy/MBq for Re-188 MAG3. Conclusions. In the event of balloon rupture, the release of Re-188 MAG3 or Re-188 DTPA results in lower radiation doses than release of Re-188 perrhenate, especially to the thyroid gland and the stomach.
引用
收藏
页码:37 / 42
页数:6
相关论文
共 25 条
[1]   Dosimetry of a radioactive coronary balloon dilitation catheter for treatment of neointimal hyperplasia [J].
Amols, HI ;
Reinstein, LE ;
Weinberger, J .
MEDICAL PHYSICS, 1996, 23 (10) :1783-1788
[2]   Dosimetric considerations for catheter-based beta and gamma emitters in the therapy of neointimal hyperplasia in human coronary arteries [J].
Amols, HI ;
Zaider, M ;
Weinberger, J ;
Ennis, R ;
Schiff, PB ;
Reinstein, LE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 36 (04) :913-921
[3]  
BOTTCHER HD, 1994, INT J RADIAT ONCOL, V29, P183
[4]   DOSE TO FETUS FROM RADIONUCLIDES IN BLADDER [J].
CLOUTIER, RJ ;
SMITH, SA ;
WATSON, EE ;
SNYDER, WS ;
WARNER, GG .
HEALTH PHYSICS, 1973, 25 (02) :147-161
[5]   THE CHEMISTRY OF RHENIUM AND TECHNETIUM AS RELATED TO THE USE OF ISOTOPES OF THESE ELEMENTS IN THERAPEUTIC AND DIAGNOSTIC NUCLEAR-MEDICINE [J].
DEUTSCH, E ;
LIBSON, K ;
VANDERHEYDEN, JL ;
KETRING, AR ;
MAXON, HR .
NUCLEAR MEDICINE AND BIOLOGY, 1986, 13 (04) :465-477
[6]   THYROID CANCER OCCURRING AS A LATE CONSEQUENCE OF HEAD-AND-NECK IRRADIATION [J].
FAVUS, MJ ;
SCHNEIDER, AB ;
STACHURA, ME ;
ARNOLD, JE ;
RYO, UY ;
PINSKY, SM ;
COLMAN, M ;
ARNOLD, MJ ;
FROHMAN, LA .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (19) :1019-1025
[7]   LOW-DOSE, BETA-PARTICLE EMISSION FROM STENT WIRE RESULTS IN COMPLETE, LOCALIZED INHIBITION OF SMOOTH-MUSCLE CELL-PROLIFERATION [J].
FISCHELL, TA ;
KHARMA, BK ;
FISCHELL, DR ;
LOGES, PG ;
COFFEY, CW ;
DUGGAN, DM ;
NAFTILAN, AJ .
CIRCULATION, 1994, 90 (06) :2956-2963
[8]  
Hsieh B. T., 1996, Nuclear Science Journal, V33, P26
[9]  
KIRSCHNER AS, 1975, J NUCL MED, V16, P248
[10]  
Knapp FF, 1997, ANTICANCER RES, V17, P1783